

Table 29: Baseline Patient Characteristics^a — Clinical Review

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
Research Questions 1 and 2						
MIGS Vs. Pharmacotherapy						
Vold et al. 2016 ⁵⁸	<p>Sample size: N = 101 eyes (101 patients) 2x iStent, n = 54</p> <p>Travoprost, n = 47</p> <p>Age: 2x iStent: 64.5 y ± 11.1 y</p> <p>Travoprost: 62.0 y ± 11.3 y</p> <p>P = NR</p> <p>Sex: n = 44 female; n = 57 male</p> <p>Race: Caucasian</p>	<p>Type of eyes: Phakic</p> <p>Type of glaucoma: POAG, n = 100; PXF, n = 1</p> <p>Note: the patient with PXF was excluded from the analysis.</p> <p>Glaucoma severity: NR</p>	<p>Previous ocular procedures: None</p> <p>Comorbidities: NR</p>	<p>2x iStent: 25.5 ± 2.5</p> <p>Travoprost: 25.1 ± 4.6</p> <p>P = NR</p>	<p>None</p>	<p>VF mean deviation (dB): 2x iStent: −7.5 ± 8.8 Travoprost: −5.8 ± 7.7</p> <p>P = NR</p> <p>BCVA (Snellen), n (%): 2x iStent: 20/40 or better, 40 (74%); 20/100 or better, 52 (96%); 20/200 or better, 54 (100%)</p> <p>Travoprost: 20/40 or better, 39 (83%); 20/100 or better, 47 (100%); 20/200 or better, 47 (100%)</p> <p>P = NR</p>
Fea et al. 2014 ³⁶	<p>Sample size: N = 192 eyes (192 patients)</p> <p>2x iStent Inject, n = 94</p>	<p>Type of eyes, n (%): 2x iStent Inject: Phakic, 92 (98%) Pseudophakic, 2 (2%)</p> <p>Latanoprost + Timolol:</p>	<p>Previous ocular procedures: NR</p> <p>Comorbidities: Cataract; others NR</p>	<p>2x iStent Inject: 25.2 ± 1.4</p> <p>Latanoprost + Timolol: 24.8 ± 1.7</p>	<p>NR</p>	<p>NR</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	<p>Two medications, n = 98</p> <p>Age: 2x iStent Inject: 64.5 y ± 10.3 y (range: 26 y to 83 y)</p> <p>Latanoprost + Timolol: 64.3 y ± 9.8 y (range: 39 y to 83 y)</p> <p><i>P</i> = NR</p> <p>Sex: n = 107 female; n = 85 male</p> <p>Race, n (%): 2x iStent Inject: White, 94 (100%)</p> <p>Latanoprost + Timolol: White, 98 (100%)</p>	<p>Phakic, 95 (97%) Pseudophakic, 3 (3%)</p> <p>Type of glaucoma: Per-protocol, OAG</p> <p>Glaucoma severity: NR</p>		<i>P</i> = NR		
MIGS Vs. Laser Therapy						
Fea et al. 2017 ⁶²	<p>Sample size: N = 56 eyes (56 patients)</p> <p>Hydrus, n = 31 eyes (31 patients)</p> <p>SLT, n = 25 eyes (25 patients)</p>	<p>Type of Eyes, n (%): Hydrus: Phakic, 20 (65%); Pseudophakic, 11 (35%)</p> <p>SLT: Phakic, 17 (68%); Pseudophakic, 8 (32%)</p>	<p>Previous ocular procedures: Hydrus: SLT, n = 1 SLT: None <i>P</i> = 0.36</p> <p>Comorbidities: NR</p>	<p>Hydrus: 23.09 ± 5.08</p> <p>SLT: 23.18 ± 2.15</p> <p><i>P</i> = 0.93</p>	<p>Hydrus: 2.29 ± 0.83</p> <p>SLT: 2.48 ± 0.92</p> <p><i>P</i> = 0.42</p>	<p>VF mean deviation (dB): Hydrus: -8.43 ± 6.84</p> <p>SLT: -3.04 ± 0.65</p> <p><i>P</i> < 0.001</p> <p>VA (logMAR):</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	Age: Hydrus: 70.8 y ± 11.83 y SLT: 69.0 y ± 11.28 y <i>P</i> = 0.56 Sex: n = 29 female; n = 27 male <i>P</i> = 0.10 Race: NR	<i>P</i> = 0.79 Type of glaucoma: Per-protocol, POAG Glaucoma severity: NR				Hydrus: 0.25 ± 0.15 SLT: 0.30 ± 0.1 <i>P</i> = 0.14
MIGS Vs. Another MIGS						
Katz et al. 2018 ⁵⁹ and Katz et al. 2015 ⁶⁰	Sample size: N = 119 eyes (119 patients) iStent, n = 38 2x iStent, n = 41 3x iStent, n = 40 Age: iStent: 68.1 y ± 9.1 y (range: 49 y to 83 y) 2x iStent: 67.8 y ± 9.3 y (range: 51 y to 83 y)	Type of Eyes, n: iStent: Phakic, 37; Pseudophakic, 1 2x iStent: Phakic, 41; Pseudophakic, 0 3x iStent: Phakic, 38; Pseudophakic, 1 <i>P</i> = NR Type of Glaucoma, n: iStent: POAG, 38; PXF, 0 2x iStent: POAG, 40; PXF, 1	Previous ocular procedures: NR Comorbidities: NR	Medicated IOP: iStent: 19.8 ± 1.3 2x iStent: 20.1 ± 1.6 3x iStent: 20.4 ± 1.8 <i>P</i> = NR Unmedicated (post-washout) IOP: iStent: 25.0 ± 1.1 2x iStent: 25.0 ± 1.7	iStent: 1.71 ± 0.61 2x iStent: 1.76 ± 0.54 3x iStent: 1.51 ± 0.69 <i>P</i> = NR	VF mean deviation (dB): iStent: −4.72 ± 4.42 2x iStent: −5.20 ± 5.65 3x iStent: −4.81 ± 4.22 <i>P</i> = NR BCVA (logMAR): iStent: 0.28 ± 0.34 2x iStent: 0.39 ± 0.40 3x iStent:

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	<p>3x iStent: 60.9 y ± 8.1 y (range: 49 y to 85 y)</p> <p><i>P</i> = NR</p> <p>Sex: n = 53 female; n = 65 male</p> <p>Race: Caucasian</p>	<p>3x iStent: POAG, 39; PXF, 0</p> <p><i>P</i> = NR</p> <p>Glaucoma severity: Per-protocol, mild to moderate</p>		<p>3x iStent: 25.1 ± 1.9</p> <p><i>P</i> = NR</p>		<p>0.24 ± 0.35</p> <p><i>P</i> = NR</p>
MIGS Vs. Filtration Surgery						
ECP Vs. Glaucoma Drainage Device						
Murakami et al. 2017 ⁶³	<p>Sample size: N = 73 eyes (73 patients)</p> <p>ECP, n = 25</p> <p>GDD-2, n = 48 (BGI 250, n = 26; BGI 350, n = 22)</p> <p>Age: ECP: 59.2 y ± 17.3 y (range: 13 y to 87 y)</p> <p>GDD-2: 60.6 y ± 15.6 y (range: 27 y to 88 y)</p> <p><i>P</i> = 0.73</p> <p>Sex: n = 31 female; n = 42 male</p>	<p>Type of eyes: Pseudophakic</p> <p>Type of Glaucoma: ECP: POAG, n = 12; CACG, n = 3; juvenile onset, n = 1; secondary, n = 9; steroid, n = 0; congenital, n = 0</p> <p>GDD-2: POAG, n = 18; CACG, n = 12; juvenile onset, n = 2; secondary, n = 13; steroid, n = 1; congenital, n = 2</p> <p>Between-group differences, all <i>P</i> > 0.05</p>	<p>Previous ocular procedures: BGI 350 (all patients); others NR</p> <p>Comorbidities: NR</p>	<p>ECP: 24.0 ± 6.2</p> <p>GDD-2: 23.5 ± 8.1</p> <p><i>P</i> = 0.85</p>	<p>Median, range:</p> <p>ECP: 3, 0 to 4</p> <p>GDD-2: 4, 0 to 5</p> <p><i>P</i> = 0.22</p>	<p>VF mean deviation: ECP (n = 10): -13.94 ± 6.32</p> <p>GDD-2 (n = 23): -17.33 ± 8.68</p> <p><i>P</i> = 0.29</p> <p>VF, PSD: ECP (n = 10): 6.96 ± 3.05</p> <p>GDD-2 (n = 23): 6.71 ± 3.07</p> <p><i>P</i> = 0.86</p> <p>VA, median (range): ECP: 20/300 (20/20-LP)</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	Race: NR	Glaucoma severity: NR				<i>GDD-2</i> : 20/300 (20/25-LP) <i>P</i> = 0.35
Lima et al. 2004 ⁶¹	<p>Sample size: N = 68 eyes (68 patients) ECP, n = 34</p> <p>AGI, n = 34</p> <p>Age: ECP: 53.76 y ± 10.4 y</p> <p>AGI: 56.64 y ± 11.33 y</p> <p><i>P</i> = 0.4</p> <p>Sex: n = 29 female; n = 39 male</p> <p>Race, n: ECP: White, 24; black, 10; Asian, 0</p> <p>AGI: White, 22; black, 10; Asian, 2</p> <p><i>P</i> = NR</p>	<p>Type of eyes: Pseudophakic</p> <p>Type of Glaucoma, n (%): ECP: Neovascular, 14 (41.17%); Pseudophakic, 10 (29.41%); associated with penetrating Keratoplasty, 8 (23.52%); associated with Vitreo-Retinal surgery, 2 (5.88%)</p> <p>AGI: Neovascular, 13 (38.23%); Pseudophakic, 10 (29.41%); associated with Penetrating Keratoplasty, 10 (29.41%); associated with Vitreo-Retinal surgery, 1 (2.9%)</p> <p><i>P</i> = 0.4</p> <p>Glaucoma severity: NR</p>	<p>Previous ocular procedures: Type of procedures not reported; number of procedures as follows:</p> <p>ECP: 3.1 ± 2.2</p> <p>AGI: 3.2 ± 2.0</p> <p><i>P</i> = 0.6</p> <p>Comorbidities: NR</p>	<p>ECP: 41.61 ± 3.42</p> <p>AGI: 41.32 ± 3.03</p> <p><i>P</i> = 0.5</p>	<p>ECP: 3.0 ± 1.3</p> <p>AGI: 3.5 ± 1.0</p> <p><i>P</i> = 0.7</p>	<p>VA (LogMAR): ECP: 0.67 ± 0.24</p> <p>AGI: 0.69 ± 0.25</p> <p><i>P</i> = 0.8</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
Trabectome (or 2x iStent Inject) Vs. Trabeculectomy						
Pahlitzsch et al. 2017 ²⁵	<p>Sample size: N = 88 eyes (88 patients)</p> <p>Trabectome, n = 43</p> <p>2x iStent Inject, n = 20</p> <p>Trabeculectomy, n = 25</p> <p>Age: Trabectome: 72.8 y ± 8.8 y</p> <p>2x iStent Inject: 68.6 y ± 16.4 y</p> <p>Trabeculectomy: 74.2 y ± 9.1 y <i>P</i> = 0.107</p> <p>Sex: n = 53 female; n = 35 male</p> <p>Race: Caucasian</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma: OAG (specific type[s] not reported)</p> <p>Glaucoma severity: NR</p>	<p>Previous ocular procedures: NR</p> <p>Comorbidities: Trabectome (n = 10): controlled hypertension, n = 9; mild dysfibrinogenemia defect without clinical impairment or bleeding complications, n = 1</p> <p>2x iStent Inject (n = 1): controlled hypertension, n = 1</p> <p>Trabeculectomy (n = 3): atopic dermatitis, n = 2; controlled hypertension, n = 1</p>	<p>Trabectome, 19.1</p> <p>2x iStent Inject, 21.3</p> <p>MIGS (Trabectome and 2x iStent Inject groups combined), 20.5</p> <p>Trabeculectomy, 28.0</p> <p>Trabeculectomy vs. MIGS, <i>P</i> = 0.097</p>	<p>Trabectome: 2.62</p> <p>2x iStent Inject: 2.45</p> <p>MIGS: 2.5</p> <p>Trabeculectomy: 2.32</p> <p>Trabeculectomy vs. MIGS: <i>P</i> = 0.476</p>	<p>VA (logMAR): Trabectome : 0.3</p> <p>2x iStent Inject : 0.3</p> <p>MIGS: 0.3</p> <p>Trabeculectomy: 0.32</p> <p>Trabeculectomy vs. MIGS: <i>P</i> = 0.609</p>
Jea et al. 2012 ⁶⁴	<p>Sample size: N = 217 eyes (217 patients)</p> <p>Trabectome, n = 115</p> <p>Trabeculectomy, n = 102</p>	<p>Type of eyes, n (%): Trabectome: Phakic, 75 (65.2%); Pseudophakic, 40 (34.8%)</p> <p>Trabeculectomy: Phakic, 67 (65.7%);</p>	<p>Previous ocular procedures, n (%): Trabectome: ALT, 8 (7.0%); SLT, 29 (25.2%), ALT and SLT, 18 (15.7%)</p>	<p>Trabectome: 28.1 ± 8.6 (range: 14 to 52)</p> <p>Trabeculectomy: 26.3 ± 10.9 (range: 10 to 52)</p>	<p>Trabectome: 3.3 ± 1.3</p> <p>Trabeculectomy: 3.4 ± 1.0</p> <p><i>P</i> = 0.289</p>	<p>VA (logMAR): Trabectome: 0.34 ± 0.40</p> <p>Trabeculectomy: 0.63 ± 0.82</p> <p><i>P</i> = 0.001</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	<p>Age: Trabectome: 63.6 y ± 16.6 y</p> <p>Trabeculectomy: 67.3 y ± 17.1 y <i>P</i> = 0.156</p> <p>Sex: n = 113 female; n = 104 male</p> <p>Race, n (%): Trabectome: White, 86 (74.8%); African American, 14 (12.2%); Hispanic, 9 (7.8%); Asian, 6 (5.2%)</p> <p>Trabeculectomy: White, 71 (69.6%); African American, 17 (16.7%); Hispanic, 8 (7.8%); Asian, 6 (5.9%)</p> <p><i>P</i> = 0.822</p>	<p>Pseudophakic, 35 (34.3%)</p> <p><i>P</i> = 0.942</p> <p>Type of glaucoma: Trabectome: POAG, 78 (67.8%); PXF, 16 (13.9%); pigment dispersion syndrome, 9 (7.8%); pigmentary, 7 (6.1%); uveitic, 5 (4.3%)</p> <p>Trabeculectomy: POAG, 71 (69.6%); PXF, 12 (11.8%); pigment dispersion syndrome, 6 (5.9%); pigmentary, 8 (7.8%); uveitic, 5 (4.9%)</p> <p><i>P</i> = 0.940</p> <p>Glaucoma severity: NR</p>	<p>Trabeculectomy: ALT, 4 (3.9%); SLT, 21 (20.6%), ALT and SLT, 6 (5.9%)</p> <p><i>P</i> = 0.031</p> <p>Comorbidities, n (%): Trabectome: Hypertension, 41 (35.7%); Diabetes, 16 (13.9%)</p> <p>Trabeculectomy: Hypertension, 43 (42.2%); diabetes, 18 (17.6%)</p> <p><i>P</i> = 0.333 (hypertension) <i>P</i> = 0.461 (diabetes)</p>	<i>P</i> = 0.190		
Xen45 Vs. Trabeculectomy						
Schlenker et al. 2017 ⁶⁵	<p>Sample size: N = 354 eyes (293 patients)</p> <p>Xen45, n = 185 eyes (159 patients)</p> <p>Trabeculectomy, n = 169</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma: Xen45, n (%): POAG, 106 (57.3%); PXF, 38 (20.5%); pigment dispersion, 10 (5.4%);</p>	<p>Previous ocular procedures, n (%): Xen45: Laser peripheral iridotomy, 13 (7.0%); cataract surgery, 63 (34.1%); laser trabeculectomy, 97</p>	<p>Median IOP [IQR]: Xen45: 24.0 [19.0, 30.0]</p> <p>Trabeculectomy: 24.0 [19.0, 32.0]</p> <p><i>P</i> = 0.32</p>	NR	<p>VF mean deviation, median (IQR): Xen45, -6.9 (-13.6 to -3.3)</p> <p>Trabeculectomy: -6.0 (-16.0 to -2.8)</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	<p>eyes (139 patients)</p> <p>Age: Xen45 (median age, IQR): 65.0 y, 53.7 y to 73.6 y</p> <p>Trabeculectomy (median age, IQR): 67.2 y, 59.2 y to 74.8 y</p> <p><i>P</i> = 0.038</p> <p>Sex: n = 178 female; n = 176 male</p> <p>Race, n (%): XEN 45: White, 148 (80.0%); Asian, 18 (9.7%); black, 8 (4.3%); Latino and otherwise unspecified, 11 (6.0%)</p> <p>Trabeculectomy: White, 131 (77.5%); Asian, 20 (11.8%); black, 13 (7.7%); Latino and otherwise unspecified, 5 (3.0%)</p> <p><i>P</i> = 0.42</p>	<p>PACG, 0 (0%); combined mechanisms, 13 (7.1%); normal tension, 4 (2.2%); juvenile OAG, 10 (5.4%); other, 4 (2.2%)</p> <p>Trabeculectomy, n (%): POAG, 96 (56.8%); PXF, 42 (24.8%); pigment dispersion, 10 (5.9%); PACG, 4 (2.4%); combined mechanisms, 7 (4.1%); normal tension, 4 (2.4%); juvenile OAG, 2 (1.2%); other, 4 (2.4%)</p> <p><i>P</i> = 0.15</p> <p>Glaucoma severity: Xen45, n (%): mild, 85 (45.9%); moderate, 44 (23.8%); advanced, 56 (30.3%)</p>	<p>(52.4%)</p> <p>Trabeculectomy: Laser peripheral iridotomy, 20 (11.8%); cataract surgery, 56 (33.1%); laser trabeculectomy, 50 (29.6%)</p> <p><i>P</i> values for between-group differences: Laser peripheral iridotomy, <i>P</i> = 0.095; cataract surgery, <i>P</i> = 0.91; laser trabeculectomy, <i>P</i> < 0.0001</p> <p>Comorbidities, n (%): Diabetes: Xen45, 18 (9.7%); Trabeculectomy, 15 (8.9%), <i>P</i> = 0.86; others NR</p>	<p>> 21 mm Hg, n (%): Xen45, 109 (58.9%)</p> <p>Trabeculectomy, 103 (60.9%)</p> <p><i>P</i> = 0.75</p>		<p><i>P</i> = 0.96</p> <p>VA (logMAR), median (IQR): Xen45, 0.2 (0.1 to 0.3)</p> <p>Trabeculectomy: 0.2 (0.1 to 0.6)</p> <p><i>P</i> = 0.039</p> <p>BCVA 0.4 logMAR or worse, n (%): Xen45, 40 (21.6%)</p> <p>Trabeculectomy: 54 (32.0%)</p> <p><i>P</i> = 0.031</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
		Trabeculectomy, n (%): mild, 83 (49.1%); moderate, 25 (14.8%); advanced, 61 (36.1%) <i>P</i> = 0.093				
Research Questions 3 and 4						
MIGS + Phaco Vs. Phaco Alone						
ECP + Phaco Vs. Phaco Alone						
Kang et al. 2017 ⁷²	Sample size: N = 124 eyes (114 patients) ECP + Phaco, n = 62 eyes (10 patients had bilateral surgery) Phaco, n = 62 eyes Age: ECP + Phaco, 76 y ± 12 y Phaco, 74 y ± 11 y <i>P</i> = NR Sex: n = 61 female; n = 53 male Race: NR	Type of eyes: NR Type of glaucoma: NR; OAG (including normal tension, PXF and pigmentary) were eligible Glaucoma severity: NR	Previous ocular procedures: ECP + Phaco: 15 patients (27.8%) had previous glaucoma procedures (13 Trabeculectomy with or without MMC, 1 Argon laser trabeculoplasty, 1 transscleral cyclodiode laser) Phaco: None Comorbidities: Cataract; others NR	ECP + Phaco: 20.4 ± 6.25 Phaco: NR	ECP + Phaco: 2.7 ± 0.9 Phaco: NR	VF (dB), mean (range): ECP + Phaco: -17.01 (-2.44 to -30.2); Phaco: NR

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
Perez Bartolome et al. 2017 ⁷³	<p>Sample size: N = 99 eyes (99 patients)</p> <p>ECP + Phaco, n = 69</p> <p>Phaco, n = 30</p> <p>Age: ECP + Phaco: 73.94 y ± 8.75 y (range: 52 y to 90 y)</p> <p>Phaco: 71.6 y ± 4.65 y (range: 60 y to 80 y) P = 0.096</p> <p>Sex: n = 48 female; n = 51 male</p> <p>Race, n (%): ECP + Phaco: Caucasian, 40 (57.97%); black, 22 (31.88%); Asian or mixed race, 7 (10.15%)</p> <p>Phaco: Caucasian, 11 (36.66%); black, 15 (50%); Asian or mixed race, 4 (13.34%)</p> <p>P = 0.144</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma: Per-protocol, POAG</p> <p>Glaucoma severity: NR as categorical variable; HVF mean deviation meant to reflect “disease severity” and was significantly greater in the ECP + Phaco group (see last column)</p> <p>Note: The Phaco group included those with early-stage glaucoma; the ECP + Phaco group included those with uncontrolled glaucoma or previous failed surgery.</p>	<p>Previous ocular procedures, n (%): ECP + Phaco: None, 48 (69.56%); Trabeculectomy, 9 (13.04%); needling, 3 (4.35%); SLT, 4 (5.79%); GDD, 3 (4.35%); transscleral cyclophotocoagulation, 2 (2.91%); total with previous surgery, 21 (30.4%)</p> <p>Phaco: None, 27 (90%); Trabeculectomy, 2 (6.66%); needling, 0 (0%); SLT, 1 (3.33%); GDD, 0 (0%); transscleral cyclophotocoagulation, 0 (0%); total with previous surgery, 3 (10.0%)</p> <p>P = 0.028</p> <p>Comorbidities: Cataract; others NR</p>	<p>Values reported in study Table 1 (and text):</p> <p>ECP + Phaco: 21.48 ± 5.41 (range: 12 to 38)</p> <p>Phaco: 18.43 ± 3.68 (range: 10 to 24)</p> <p>P = 0.005</p> <p>Values reported in study Table 2:</p> <p>ECP + Phaco: 21.48 ± 5.56</p> <p>Phaco: 18.43 ± 3.68</p> <p>P = NR</p>	<p>Values reported in study Table 1:</p> <p>ECP + Phaco: 2.62 ± 0.82 (range: 1 to 4)</p> <p>Phaco: 1.2 ± 0.8 (range: 0 to 3)</p> <p>P < 0.001</p> <p>Values reported in study Table 2:</p> <p>ECP + Phaco: 2.61 ± 0.82</p> <p>Phaco: 1.2 ± 0.805</p> <p>P = NR</p>	<p>VF - HFV mean deviation (dB): ECP + Phaco: -13.36 ± 7.05 (range: -0.98 to -30.79) n = 68</p> <p>Phaco: -4.74 ± 2.68 (range: -1.45 to -13) n = 25</p> <p>P < 0.001</p> <p>VA (logMAR):</p> <p>Values reported in study Table 1: ECP + Phaco: 0.33 ± 0.25 (range: 0.1 to 1.0)</p> <p>Phaco: 0.44 ± 0.3 (range: 0.1 to 1.0)</p> <p>P = 0.079</p> <p>Values reported in study Table 2: ECP + Phaco: 0.33 ± 0.25</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
						Phaco: 0.42 ± 0.2 P = NR
Sheybani et al. 2015 ⁷⁴	<p>Sample size: N = 141 eyes (141 patients)</p> <p>ECP + Phaco, n = 83</p> <p>Phaco, n = 58</p> <p>Age: ECP + Phaco: 75 y (range: 54 y to 91 y)</p> <p>Phaco: 73 y (range: 42 y to 90 y)</p> <p>P = 0.186</p> <p>Sex: n = 62 female; n = 79 male</p> <p>Race, n (%): ECP + Phaco: African American, 27 (33%); white/other, 56 (67%)</p> <p>Phaco: African American, 11</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma: Per-protocol, OAG</p> <p>Glaucoma severity: Per-protocol, mild to moderate</p>	<p>Previous ocular procedures: None</p> <p>Comorbidities: Cataract; others NR</p>	<p>IOP average over 3 visits:</p> <p>ECP + Phaco: 17.6 ± 9.0</p> <p>Phaco: 16.1 ± 4.2</p> <p>P = 0.083</p>	<p>ECP + Phaco: 2.0 (range: 0 to 3)</p> <p>Phaco: 0.4 (range: 0 to 3)</p> <p>P < 0.001</p>	<p>BCVA (logMAR): ECP + Phaco: 0.382</p> <p>Phaco: 0.358</p> <p>P = 0.608</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	(19%); white/other, 47 (81%) <i>P</i> = NS					
Siegel et al. 2015 ⁷⁵	<p>Sample size: N = 313 eyes (161 patients)</p> <p>ECP + Phaco, n = 261 eyes (134 patients)</p> <p>Phaco, n = 52 eyes (27 patients)</p> <p>Age: ECP + Phaco: 74.8 y ± 8.0 y</p> <p>Phaco: Reported as 78.0 y ± 8.1 y in a table, and as 78.1 y ± 8.1 y in the text</p> <p><i>P</i> = 0.06</p> <p>Sex: n = 100 female; n = 61 male</p> <p>Race, n (%): ECP + Phaco: Caucasian, 90 (67.2%); African American, 39 (29.1%); other, 5 (3.7%)</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma, n (%): ECP + Phaco: POAG, 113 (84.4%); CACG, 3 (2.2%); normal-tension glaucoma, 13 (9.7%); other OAG, 5 (3.7%)</p> <p>Phaco: POAG, 15 (55.6%); CACG, 2 (7.4%); normal-tension glaucoma, 5 (18.5%); other OAG, 5 (18.5%)</p> <p><i>P</i> = 0.54</p> <p>Glaucoma severity: Per-protocol, mild to moderate</p>	<p>Previous ocular procedures: NR</p> <p>Comorbidities: Cataract; others NR</p>	<p>ECP + Phaco: 17.2 ± 4.8</p> <p>Phaco: 17.7 ± 4.4</p> <p><i>P</i> = 0.52</p>	<p>ECP + Phaco: 1.3 ± 0.6</p> <p>Phaco: 1.5 ± 0.7</p> <p>Reported as <i>P</i> = 0.22 in study Table 1 and <i>P</i> = 0.02 in study Table 2</p>	<p>Median VA (Snellen): ECP + Phaco: 20/50</p> <p>Phaco: 20/60</p> <p><i>P</i> = 0.10</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	Phaco: Caucasian, 18 (66.7%); African American, 8 (29.6%); other, 1 (3.7%) <i>P</i> = 0.10					
Francis et al. 2014 ⁸⁴	Sample size: N = 160 eyes (160 patients) ECP + Phaco, n = 80 Phaco alone, n = 80 Age: ECP + Phaco: 70.0 y ± 6.3 y (range: 55 y to 84 y) Phaco alone: 69.7 y ± 6.9 y (range: 56 y to 84 y) <i>P</i> = 0.76 Sex: n = 75 female n = 85 male Race: NR	Type of eyes: NR Type of glaucoma: POAG Glaucoma severity: Per-protocol, mild to moderate	Previous ocular procedures: NR Comorbidities: Cataract; others NR	ECP + Phaco: 18.1 ± 3.0 Phaco alone: 18.1 ± 3.0 <i>P</i> = 1.0	ECP + Phaco: 1.5 ± 0.8 Phaco alone: 2.4 ± 1.0 <i>P</i> < 0.001	NR
1x or 2x iStent + Phaco Vs. Phaco Alone						
El Wardani et al. 2015 ⁷⁶	Sample size: N = 131 eyes (105 patients)	Type of eyes: NR	Previous ocular procedures: NR	iStent + Phaco: 17.5 2x iStent + Phaco: 17.0	iStent + Phaco: 1.8 2x iStent + Phaco: 2.1	Median VA: iStent + Phaco: 0.4

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	<p>iStent + Phaco, n = 31 eyes (27 patients)</p> <p>2x iStent + Phaco, n = 22 eyes (21 patients)</p> <p>Phaco alone, n = 78 eyes (61 patients)</p> <p>Age: iStent + Phaco: 68.3 y</p> <p>2x iStent + Phaco: 69.1 y</p> <p>Phaco alone: 71.1 y</p> <p><i>P</i> = NS</p> <p>Sex: n = 64 female eyes; n = 67 male eyes</p> <p>Race: NR</p>	<p>Type of glaucoma, n (%): iStent + Phaco: POAG, 8 (26%); PACG, 13 (42%); PXF, 2 (7%); pigmentary, 1 (3%); ocular hypertension, 6 (19%); normal-tension glaucoma, 1 (3%)</p> <p>2x iStent + Phaco: POAG, 5 (23%); PACG, 10 (45%); PXF, 2 (9%); pigmentary, 0 (0%); ocular hypertension, 3 (14%); normal-tension glaucoma, 2 (9%)</p> <p>Phaco alone: POAG, 22 (28%); PACG, 37 (47%); PXF, 10 (13%); pigmentary, 2 (3%); ocular hypertension, 6 (8%); normal-tension glaucoma, 1 (1%)</p> <p><i>P</i> = 0.95</p> <p>Glaucoma severity: Per-protocol, mild to moderate</p>	<p>Comorbidities: NR</p>	<p>Phaco: 16.3</p> <p><i>P</i> = NS</p>	<p>Phaco: 1.9</p> <p><i>P</i> = NS</p>	<p>2x iStent + Phaco: 0.5</p> <p>Phaco: 0.3</p> <p><i>P</i> = NR</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
Fea et al. 2015 ⁶⁶ and Fea 2010 ⁶⁷	<p>Sample size: N = 36 eyes (36 patients)</p> <p>iStent + Phaco, n = 12</p> <p>Phaco, n = 24</p> <p>Age: iStent + Phaco: 64.5 y ± 3.4 y (range: 60 y to 70 y)</p> <p>Phaco: 64.9 y ± 3.1 y (range: 59 y to 71 y)</p> <p>P = NR</p> <p>Sex: n = 23 female; n = 13 male</p> <p>Race: NR</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma: Per-protocol, POAG</p> <p>Glaucoma severity: NR</p>	<p>Previous ocular procedures: Per-protocol, none</p> <p>Comorbidities: NR</p>	<p>IOP before medication washout: iStent + Phaco: 17.9 ± 2.6</p> <p>Phaco: 17.3 ± 3.0</p> <p>P = 0.512</p>	<p>iStent + Phaco: 2.0 ± 0.9</p> <p>Phaco: 1.9 ± 0.7</p> <p>P = NS</p>	<p>Per-protocol, VA no better than 0.6 (20/80)</p>
Craven et al. 2012 ⁶⁸ and Samuelson et al. 2011 ³⁴	<p>Sample size: N = 240 eyes (239 patients)</p> <p>iStent + Phaco, n = 117</p> <p>Phaco alone, n = 123</p> <p>Age: iStent + Phaco: 74 y ± 8 y</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma: Per-protocol, POAG</p> <p>Additional glaucoma diagnosis: iStent + Phaco: Pigmentary, 4 (3%); PXF, 7 (6%)</p>	<p>Previous ocular procedures: NR</p> <p>Comorbidities, n (%): Per-protocol, cataracts</p> <p>Other ocular comorbidities in complete sample (“distributed similarly between groups” p.</p>	<p>Screening IOP (medicated): iStent + Phaco: 18.7 ± 3.3 (range: 9.5 to 24)</p> <p>Phaco alone: 18.0 ± 3.0 (range: 12 to 24) P = 0.103</p>	<p>Screening visit Medications: iStent + Phaco: 1.5 ± 0.7 (range: 1 to 3)</p> <p>Phaco alone: 1.5 ± 0.6 (range: 1 to 3) P = 0.451</p>	<p>VF PSD (dB): iStent + Phaco: 2.89 ± 1.79</p> <p>Phaco alone: 2.79 ± 1.90 P = NR</p> <p>VF mean deviation (dB): iStent + Phaco: -3.75 ± 3.03</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	<p>(range: 53 y to 88 y)</p> <p>Phaco alone: 73 y ± 9 y (range: 48 y to 88 y) <i>P</i> = 0.314</p> <p>Sex: n = 142 female; n = 98 male</p> <p>Race: iStent + Phaco: American Indian or Alaska Native, 1 (1%); Asian, 1 (1%); black or African American, 15 (13%); Native Hawaiian or Pacific Islander, 1 (1%); Hispanic or Latino, 16 (14%); white, 83 (71%)</p> <p>Phaco alone: American Indian or Alaska Native, 1 (1%); Asian, 0 (0%); black or African American, 19 (15%); Native Hawaiian or Pacific Islander, 0 (0%); Hispanic or Latino, 15 (12%); white, 88 (72%)</p> <p><i>P</i> = 0.891</p>	<p>Phaco alone: Pigmentary, 3 (2%); PXF, 7 (6%) <i>P</i> = 0.939</p> <p>Glaucoma severity: Mild to moderate</p>	<p>462³⁴: posterior vitreous detachment, 42 (18%); dry eye, 31 (13%); AMD, 25 (10%)</p>	<p>Unmedicated IOP: iStent + Phaco: 25.2 ± 3.5 (range: 21 to 36)</p> <p>Phaco alone: 25.5 ± 3.7 (range: 22 to 36) <i>P</i> = 0.517</p>		<p>Phaco alone: −3.74 ± 3.86 <i>P</i> = 0.983</p> <p>BCVA (logMAR): iStent + Phaco: 0.35 ± 0.21 (range: −0.10 to 1.00)</p> <p>Phaco alone: 0.36 ± 0.26 (range: −0.16 to 1.74) <i>P</i> = 0.797</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
Fernandez-Barrientos et al. 2010 ⁶⁹	<p>Sample size: N = 33 eyes (33 patients)</p> <p>2x iStent + Phaco, n = 17</p> <p>Phaco alone, n = 16</p> <p>Age: 2x iStent + Phaco: 75.2 y ± 7.2 y (range: 63 y to 86 y)</p> <p>Phaco alone: 76.7 y ± 5.8 y (range: 64 y to 89 y)</p> <p><i>P</i> = 0.5</p> <p>Sex: n = 18 female; n = 15 male</p> <p>Race: NR</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma: Per-protocol, POAG or ocular hypertension</p> <p>Glaucoma severity, n (%):</p> <p>2x iStent + Phaco: Ocular hypertension, 2 (11.8%); early glaucoma, 7 (41.2%), moderate glaucoma, 4 (23.5%); advanced glaucoma, 3 (17.6%); severe glaucoma, 1 (5.9%)</p> <p>Phaco alone: Ocular hypertension, 1 (6.3%); early glaucoma, 11 (68.8%), moderate glaucoma, 3 (18.8%); advanced glaucoma, 1 (6.3%); severe glaucoma, 0 (0%)</p> <p><i>P</i> = 0.5</p>	<p>Previous ocular procedures: None</p> <p>Comorbidities: Cataract, others NR</p>	<p>Unmedicated IOP:</p> <p>2x iStent + Phaco: 24.2 ± 1.8</p> <p>Phaco alone: 23.6 ± 1.5</p> <p><i>P</i> = 0.18</p>	<p>2x iStent + Phaco: 1.1 ± 0.5 (range: 0 to1)</p> <p>Phaco alone: 1.2 ± 0.7 (range: 0 to2)</p> <p><i>P</i> = 0.66</p>	NR
Hydrus Microstent + Phaco Vs. Phaco Alone						
Samuelson et al. 2018 ⁸⁸	<p>Sample size: N = 556 eyes (665 patients)</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma: Per-protocol, POAG</p>	<p>Previous ocular procedures, n (%): Hydrus + Phaco: SLT, 58 (15.7%)</p>	<p>Medicated IOP: Hydrus + Phaco: 17.9 ± 3.1 Median: 18.0</p>	<p>Hydrus + Phaco: 1.7 ± 0.9</p> <p>Phaco alone:</p>	<p>VF mean deviation (dB): Hydrus + Phaco: -3.61 ± 2.49</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	<p>Hydrus + Phaco, n = 369</p> <p>Phaco alone, n = 187</p> <p>Age: Hydrus + Phaco: 71.1 ± 7.9 y</p> <p>Phaco alone: 71.2 y ± 7.6 y</p> <p><i>P</i> = NS</p> <p>Sex: n = 311 female; n = 245 male</p> <p>Race, n (%): Hydrus + Phaco: Asian, 21 (5.7%); black or African American, 45 (12.2%); white, 291 (78.9%); other, 12 (3.3%)</p> <p>Phaco alone: Asian, 11 (5.9%); black or African American, 15 (8.0%); white, 153 (81.8%); other, 8 (4.3%)</p> <p><i>P</i> = NS</p>	<p>Glaucoma severity: Per-protocol, mild to moderate</p>	<p>Phaco alone: SLT, 28 (15.0%)</p> <p><i>P</i> = NS</p> <p>Comorbidities: Cataract, others NR</p>	<p>Phaco alone: 18.1 ± 3.1 Median: 18.0</p> <p><i>P</i> = NS</p> <p>Washed-out modified DIOP: Hydrus + Phaco: 25.5 ± 3.0</p> <p>Phaco alone: 25.4 ± 2.9</p> <p><i>P</i> = NS</p>	<p>1.7 ± 0.9</p> <p><i>P</i> = NS</p>	<p>Phaco alone: -3.61 ± 2.60</p> <p><i>P</i> = NS</p> <p>VF PSD (dB): Hydrus + Phaco: 3.18 ± 2.18</p> <p>Phaco alone: 3.13 ± 1.85</p> <p><i>P</i> = NS</p> <p>BCVA (Snellen): Hydrus + Phaco: 20/40 Min, 20/240 Max, 20/14</p> <p>Phaco alone: 20/40 Min, 20/138 Max, 20/16</p> <p><i>P</i> = NS</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
Pfeiffer et al. 2015 ⁷¹	<p>Sample size: N = 100 eyes (100 patients)</p> <p>Hydrus + Phaco, n = 50</p> <p>Phaco, n = 50</p> <p>Age: Hydrus + Phaco: 72.8 y ± 6.6 y</p> <p>Phaco: 71.5 y ± 6.9 y</p> <p><i>P</i> = 0.3498</p> <p>Sex: n = 51 female; n = 49 male</p> <p>Race, n (%): Hydrus + Phaco: White, 48 (96.0%); Hispanic, 1 (2.0%); Asian, 1 (2.0%)</p> <p>Phaco: White, 49 (98.0%); Hispanic, 0 (0.0%); Asian, 0 (0.0%)</p> <p>All <i>P</i> = 1.000</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma, n (%): Hydrus + Phaco: POAG, 45 (90.0%); PXF, 5 (10.0%); Pigmentary glaucoma, 0 (0%); previous trabeculectomy, 0 (0%)</p> <p>Phaco: POAG, 41 (82.0%); PXF, 8 (16.0%); Pigmentary glaucoma, 1 (2.0%); previous trabeculectomy, 1 (2.0%)</p> <p>All <i>P</i> > 0.39</p> <p>Glaucoma severity: NR</p>	<p>Previous ocular procedures: One patient had previous trabeculectomy in the Phaco group; otherwise, NR</p> <p>Comorbidities: NR</p>	<p>Medicated IOP: Hydrus + Phaco: 18.9 ± 3.3</p> <p>Phaco: 18.6 ± 3.8</p> <p><i>P</i> = 0.6517</p> <p>Washed-out DIOP: Hydrus + Phaco: 26.3 ± 4.4</p> <p>Phaco: 26.6 ± 4.2</p> <p><i>P</i> = 0.7147</p>	<p>Hydrus + Phaco: 2.0 ± 1.0</p> <p>Phaco: 2.0 ± 1.1</p> <p><i>P</i> = 0.7619</p>	<p>VF mean deviation: Hydrus + Phaco: −5.6 ± 5.4</p> <p>Phaco: −8.4 ± 7.8</p> <p><i>P</i> = 0.0449</p> <p>VF PSD: Hydrus + Phaco: 5.1 ± 4.6</p> <p>Phaco: 5.2 ± 4.3</p> <p><i>P</i> = 0.9589</p> <p>BCVA: Hydrus + Phaco: 20/44 (range: 20/13 to 20/160)</p> <p>Phaco: 20/40 (range: 20/16 to 20/400)</p> <p><i>P</i> = 0.3784</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
Other Comparisons (From Single Studies)						
<p>Vold et al. 2016⁷⁰</p> <p>Note: The CyPass Micro-Stent was voluntarily withdrawn from the global market by the manufacturer in August 2018 due to five-year data from this study;^{37,38} however, at the time of report publication, this device was still active in the MDALL and is therefore included in this report.</p>	<p>Sample size: N = 505 eyes (505 patients)</p> <p>CyPass Micro-Stent + Phaco, n = 374</p> <p>Phaco alone, n = 131</p> <p>Age: CyPass Micro-Stent + Phaco, 70 y ± 8 y</p> <p>Phaco alone, 70 y ± 8 y</p> <p><i>P</i> > 0.05</p> <p>Sex: n = 269 female; n = 236 male</p> <p>Race, n (%): CyPass Micro-Stent + Phaco: American Indian or Alaska Native, 4 (1%); Asian, 5 (1%); black or African American, 36 (10%); Hispanic or Latino, 15 (4%); Native Hawaiian or other Pacific Islander, 0 (0%); white,</p>	<p>Type of eyes: NR</p> <p>Glaucoma type: Per-protocol, POAG</p> <p>Glaucoma severity: “mild-to-moderate” (p. 2103); explicit values NR</p>	<p>Previous ocular procedures: Per-protocol, none except laser trabeculoplasty (numbers NR)</p> <p>Comorbidities: Cataract; no other ocular pathologies; others NR</p>	<p>Unmedicated baseline DIOP: CyPass Micro-Stent + Phaco: 24.4 ± 2.8 (range: 21.0 to 33.0)</p> <p>Phaco alone: 24.5 ± 3.0 (range: 21.0 to 32.3)</p> <p><i>P</i> > 0.05</p>	<p>CyPass Micro-Stent + Phaco: 1.4 ± 0.9</p> <p>Phaco alone: 1.3 ± 1.0</p> <p><i>P</i> > 0.05</p>	<p>VF mean deviation (dB): CyPass Micro-Stent + Phaco: -3.37 ± 2.90 (range: -15.5 to 2.03)</p> <p>Phaco alone: -3.77 ± 3.07 (range: -15.5 to 0.79)</p> <p><i>P</i> > 0.05</p> <p>Medium BAT or BCVA (where BAT unavailable) at screening: CyPass Micro-Stent + Phaco: Mean logMAR: 0.517 ± 0.263 Mean Snellen: 20/66</p> <p>Phaco alone: Mean logMAR: 0.541 ± 0.268 Mean Snellen: 20/70</p> <p><i>P</i> > 0.05</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	<p>314 (84%); other (Caribbean), 0 (0%)</p> <p>Phaco alone: American Indian or Alaska Native, 2 (2%); Asian, 1 (1%); black or African American, 11 (8%); Hispanic or Latino, 7 (5%); Native Hawaiian or other Pacific Islander, 1 (1%); white, 108 (82%); other (Caribbean), 1 (0%)</p> <p><i>P</i> > 0.05</p>					
MIGS + Phaco Vs. A Different MIGS + Phaco						
Goniotomy With Kahook Dual Blade + Phaco Vs. iStent + Phaco						
Dorairaj et al. 2018 ⁸⁶	<p>Sample size: N = 435 eyes (318 patients)</p> <p>KDB + Phaco, n = 237</p> <p>iStent + Phaco, n = 198</p> <p>Age: KDB + Phaco: 70.1 y ± 8.9 y</p> <p>iStent + Phaco: 71.3 y ± 8.1 y</p> <p><i>P</i> = 0.169</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma, n (%): KDB + Phaco: POAG, 178 (75.1%); exfoliation, 17 (7.2%); Pigmentary, 15 (6.3%); angle closure, 14 (5.9%); normal tension, 6 (2.5%); C=congenital, 1 (0.9%); others, 6 (2.5%)</p>	<p>Previous ocular procedures: NR</p> <p>Comorbidities: Cataract; others NR</p>	<p>KDB + Phaco: 17.9 ± 4.4</p> <p>iStent + Phaco: 16.7 ± 4.4</p> <p><i>P</i> = NR</p>	<p>KDB + Phaco: 1.7 ± 0.9</p> <p>iStent + Phaco: 1.9 ± 0.9</p> <p><i>P</i> > 0.05</p>	<p>BCVA (logMAR): Complete sample: 0.4 ± 0.3</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	<p>Sex: n = 257 female; n = 178 male</p> <p>Race, n (%): KDB + Phaco: Caucasian, 110 (46.4%); Hispanic, 63 (26.6%); black, 42 (17.7%); Asian, 14 (5.9%); others, 8 (3.4%)</p> <p>iStent + Phaco: Caucasian, 119 (60.1%); Hispanic, 34 (17.2%); black, 34 (17.2%); Asian, 7 (3.5%); others, 4 (2.0%)</p> <p><i>P</i> = 0.038</p>	<p>iStent + Phaco: POAG, 177 (89.4%); exfoliation, 3 (1.5%); Pigmentary, 4 (2.0%); angle closure, 0 (0.0%); normal tension, 4 (2.0%); congenital, 0 (0.0%); others, 10 (5.1%)</p> <p><i>P</i> < 0.001</p> <p>Glaucoma severity, n (%; defined by ICD-9 definitions): KDB + Phaco: mild, 117 (49.4%); moderate, 120 (50.6%)</p> <p>iStent + Phaco: Mild, 85 (49.1%); moderate, 88 (50.9%)</p> <p><i>P</i> = 0.095</p>				
Trabectome + Phaco Vs. 2x iStent + Phaco						
Kurji et al. 2017 ⁷⁹	<p>Sample size: N = 70 eyes (55 patients)</p> <p>Trabectome + Phaco, n = 36 eyes (30 patients)</p> <p>2x iStent + Phaco,</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma, number of patients: Trabectome + Phaco, POAG, n = 14; PXF, n = 16 patients</p>	<p>Previous ocular procedures, number of eyes:</p> <p>Trabectome + Phaco: SLT, n = 17 ALT, n = 3</p>	<p>Trabectome + Phaco: 20.92 ± 5.07</p> <p>2x iStent + Phaco: 17.47 ± 4.87</p> <p><i>P</i> = 0.026</p>	<p>Trabectome + Phaco: 2.25 ± 1.34</p> <p>2x iStent + Phaco: 2.15 ± 1.21</p> <p><i>P</i> = 0.21</p>	<p>VA: Trabectome + Phaco: 0.36 ± 0.27 logMAR</p> <p>iStent + Phaco: NR</p> <p><i>P</i> > 0.05</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	<p>n = 34 eyes (25 patients)</p> <p>Age: Trabectome + Phaco: 72.41 y ± 9.63 y</p> <p>2x iStent + Phaco: 75.02 y ± 10.34 y P = 0.42</p> <p>Sex: n = 28 female; n = 27 male</p> <p>Race: NR</p>	<p>2x iStent + Phaco: POAG, n = 14; PXF, n = 11 patients</p> <p>Glaucoma Severity, number of eyes: Trabectome + Phaco: Mild, n = 5 moderate, n = 20 advanced, n = 11</p> <p>2x iStent + Phaco: Mild, n = 5 moderate, n = 14 advanced, n = 14 P = 0.67 for each level of severity</p>	<p>2x iStent + Phaco: SLT, n = 14 ALT, n = 0</p> <p>Between-group differences in previous ocular procedures: SLT, P = 0.68; ALT, P = 0.07</p> <p>Comorbidities: Cataract; others NR</p>			
Khan et al. 2015 ⁷⁸	<p>Sample size: N = 101 eyes (101 patients)</p> <p>Trabectome + Phaco, n = 52</p> <p>2x iStent + Phaco, n = 49</p> <p>Age: Trabectome + Phaco: 76.1 y ± 12.1 y</p> <p>2x iStent + Phaco: 77.5 y ± 11.9 y</p> <p>P = 0.55</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma, n (%): Trabectome + Phaco: POAG, 50 (96%); pigmentary dispersion, 1 (2%); PXF, 1 (2%)</p> <p>2x iStent + Phaco: POAG, 38 (78%); pigmentary dispersion, 0 (0%); PXF, 11 (22%)</p> <p>P values for between-group comparisons:</p>	<p>Previous ocular procedures: NR</p> <p>Comorbidities: NR</p>	<p>Trabectome + Phaco: 20.6 ± 6.8</p> <p>2x iStent + Phaco: 19.6 ± 5.2 (SD reported as 5.2 in a table and as 5.3 in the abstract and text)</p> <p>P = 0.37</p>	<p>Trabectome + Phaco: 2.90 ± 1.10</p> <p>2x iStent + Phaco: 2.86 ± 0.91</p> <p>P = NR</p> <p>Median [IQR]:</p> <p>Trabectome + Phaco: 3.0 [2.0, 4.0]</p> <p>2x iStent + Phaco: 3.0 [2.0, 3.0]</p> <p>P = 0.53</p>	<p>VF mean deviation (dB):</p> <p>Trabectome + Phaco: -8.6 ± 9.7</p> <p>2x iStent + Phaco: -11.5 ± 8.0</p> <p>P = 0.17</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	<p>Sex: n = 58 female; n = 43 male</p> <p>Race, n (%): Trabectome + Phaco: White, 36 (70%); Other, 16 (30%)</p> <p>2x iStent + Phaco: White, 34 (69%); Other, 15 (31%)</p> <p><i>P</i> = 0.34</p>	<p>POAG, <i>P</i> = 0.47; pigmentary dispersion, <i>P</i> = 1; PXF, <i>P</i> = 0.007</p> <p>Glaucoma severity: Per-protocol, any severity</p>				
Trabectome + MICS Vs. 2x iStent Inject + MICS						
Gonnermann et al. 2017 ⁷⁷	<p>Sample size: N = 50 eyes (25 patients)</p> <p>Trabectome + MICS, n = 25</p> <p>2 iStent Inject + MICS, n = 25</p> <p>Age: Complete sample: 73.8 y ± 7.8 y</p> <p>Sex: n = 14 female; n = 13 male</p> <p>Race: Caucasian</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma: OAG (POAG, n = 19 patients; PXF, n = 8 patients)</p> <p>Glaucoma severity: Trabectome + MICS: Mild: 13 (52%); moderate: 12 (48%); advanced: 0 (0%);</p> <p>2 iStent inject + MICS: Mild: 12 (48%); moderate: 13 (52%); advanced: 0 (0%)</p>	<p>Previous ocular procedures: No surgery or laser</p> <p>Comorbidities: Cataract; no other ocular or systemic diseases</p>	<p>Trabectome + MICS: 22.3 ± 3.7 (range: 18 to 27)</p> <p>2 iStent inject + MICS: 21.3 ± 4.1 (range: 16 to 34)</p> <p><i>P</i> = NR</p>	<p>Trabectome + MICS: 2.1 ± 1.0 (range: 0 to 4)</p> <p>2 iStent inject + MICS: 2.0 ± 0.9 (range: 0 to 4)</p> <p><i>P</i> = NR</p>	<p>BCVA, number (%): Trabectome + MICS: ≥ 20/40: 12 (48%); 20/50 to 20/100: 13 (52%); ≥ 20/200: 0 (0%)</p> <p>2 iStent inject + MICS: ≥ 20/40: 14 (56%); 20/50 to 20/100: 11 (44%); ≥ 20/200: 0 (0%)</p> <p><i>P</i> = NR</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
Different Numbers of iStents + Phaco						
Vlasov and Kim 2017 ⁸⁰	<p>Sample size: N = 69 eyes (69 patients)</p> <p>iStent + Phaco, n = 39</p> <p>2x iStent + Phaco, n = 30</p> <p>Age: iStent + Phaco, 74.23 y ± 10.2 y</p> <p>2x iStent + Phaco, 70.26 y ± 9.64 y</p> <p>P = 0.0974</p> <p>Sex: n = 27 female; n = 42 male</p> <p>Race: NR</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma: Per-protocol, POAG, PXF, pigmentary dispersion glaucoma (numbers NR)</p> <p>Glaucoma severity: Per-protocol, any stage</p>	<p>Previous ocular procedures: NR</p> <p>Comorbidities: NR</p>	<p>Values reported in study Table 1:</p> <p>iStent + Phaco, 16.67 ± 4.1</p> <p>2x iStent + Phaco, 18.33 ± 3.99</p> <p>P = 0.0870</p> <p>Values reported in study Table 2:</p> <p>iStent + Phaco, 16.67 ± 3.82</p> <p>2x iStent + Phaco, 18.33 ± 3.99</p> <p>P = 0.4996</p>	<p>iStent + Phaco: 2.33 ± 1.4</p> <p>2x iStent + Phaco : 2.37 ± 1.30</p> <p>P = 0.9205</p>	<p>BCVA (logMAR):</p> <p>iStent + Phaco: 0.32 ± 0.23</p> <p>2x iStent + Phaco: 0.38 ± 0.25</p> <p>P = 0.7484</p>
Belovay et al. 2012 ⁸³	<p>Sample size: N = 53 eyes (47 patients)</p> <p>2x iStent + Phaco, n = 28 eyes (26 patients)</p> <p>3x iStent + Phaco, n = 25 eyes (23 patients)</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma, n (%):</p> <p>2x iStent + Phaco: POAG, 21 (75%); PXF, 7 (25%); mixed mechanism, 0 (0%)</p> <p>3x iStent + Phaco: POAG, 16 (64%);</p>	<p>Previous ocular procedures, n (%):</p> <p>2x iStent + Phaco: LPI, 4 (14%); ALT, 6 (21%); SLT, 7 (25%)</p> <p>3x iStent + Phaco: LPI, 7 (28%); ALT, 3 (12%); SLT, 10 (40%)</p>	<p>2x iStent + Phaco: 17.3 ± 4.0</p> <p>3x iStent + Phaco: 18.6 ± 4.0</p> <p>P = 0.24</p>	<p>2x iStent + Phaco: 2.8 ± 0.8</p> <p>3x iStent + Phaco: 2.6 ± 1.2</p> <p>P = 0.70</p>	<p>CDVA, n (%):</p> <p>2x iStent + Phaco: 20/40 or better, 6 (21%); 20/50 to 20/100, 15 (54%); 20/200 or worse, 7 (25%)</p> <p>3x iStent + Phaco: 20/40 or better, 8 (32%); 20/50 to 20/100, 11 (44%); 20/200 or worse, 6 (23%)</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	<p>Age: 2x iStent + Phaco: 78.8 y ± 7.0 y</p> <p>3x iStent + Phaco: 75.0 y ± 7.3 y</p> <p><i>P</i> = 0.07</p> <p>Sex: n = 33 female n = 14 male</p> <p>Race, n (%): 2x iStent + Phaco: White, 18 (69%); black, 4 (15%); South Asian, 2 (8%); Far East Asian, 2 (8%)</p> <p>3x iStent + Phaco: White, 11 (48%); black, 4 (17%); South Asian, 5 (22%); Far East Asian, 3 (13%)</p> <p><i>P</i> = 0.43</p>	<p>PXF, 7 (28%); mixed mechanism, 2 (8%)</p> <p><i>P</i> values for between-group comparisons: POAG, <i>P</i> = 0.55; PXF, <i>P</i> = 1.00; mixed mechanism, <i>P</i> = NR</p> <p>Glaucoma severity, n: Overall sample: Mild, 8; moderate, 23; advanced, 22</p>	<p><i>P</i> values for between-group comparisons: LPI, <i>P</i> = 0.31; ALT, <i>P</i> = 0.47; SLT, <i>P</i> = 0.38</p> <p>Comorbidities: Cataract</p> <p>2x iStent + Phaco: AMD, 4 (14%); high myopia, 1 (4%); suprasellar lesion, 1 (4%); branch vein occlusion, 1 (4%); diabetic retinopathy, 0 (0%); AMD scar, 0 (0%); optic nerve head drusen, 1 (4%)</p> <p>3x iStent + Phaco: AMD, 0 (0%); High myopia, 1 (5%); suprasellar lesion, 1 (5%); branch vein occlusion, 0 (0%); diabetic retinopathy, 1 (4%); AMD scar, 1 (4%); optic nerve head drusen, 0 (0%)</p> <p><i>P</i> = NR</p>			<p><i>P</i> = 0.76</p> <p>VF mean deviation (dB): 2x iStent + Phaco: −12.6 ± 7.1</p> <p>3x iStent + Phaco: −10.2 ± 8.1</p> <p><i>P</i> = 0.24</p> <p>VF, mean PSD (dB): 2x iStent + Phaco: 7.9 ± 3.4</p> <p>3x iStent + Phaco: 5.9 ± 4.1</p> <p><i>P</i> = 0.06</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
ECP + iStent + Phaco Vs. iStent + Phaco						
Ferguson et al. 2017 ⁸¹	<p>Sample size: N = 101 eyes (76 patients)</p> <p>ECP + iStent + Phaco, n = 51 eyes (34 patients)</p> <p>iStent + Phaco, n = 50 eyes (42 patients)</p> <p>Age: ECP + iStent + Phaco: 69.65 y ± 11.46 y</p> <p>iStent + Phaco: 74.30 y ± 9.41 y P = 0.03</p> <p>Sex: n = 54 female; n = 47 male</p> <p>Race: NR</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma: OAG</p> <p>Glaucoma severity: ECP + iStent + Phaco: Mild, n = 9; moderate, n = 16; severe, n = 26</p> <p>Stent + Phaco: Mild, n = 23; moderate, n = 22; severe, n = 5</p>	<p>Previous ocular procedures: NR</p> <p>Comorbidities: Cataract; others NR</p>	<p>ECP + iStent + Phaco: 21.49 ± 9.59</p> <p>iStent + Phaco: 20.66 ± 3.23</p> <p>P = 0.56</p>	<p>ECP + iStent + Phaco: 1.78 ± 0.99</p> <p>iStent + Phaco: 1.68 ± 0.84</p> <p>P = NR</p>	NR
ECP + Phaco Vs. Trabectome + Phaco						
Moghimi et al. 2018 ⁸⁹	<p>Sample size: N = 61 eyes (61 patients)</p> <p>ECP + Phaco, n = 35</p> <p>Trabectome + Phaco, n = 26</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma, n (%): ECP + Phaco: POAG, 20 (57.1%); PXF, 15 (42.9%)</p> <p>Trabectome + Phaco: POAG, 16 (61.5%);</p>	<p>Previous ocular procedures: Per-protocol, no surgical history</p> <p>Comorbidities: Cataract; others NR</p>	<p>ECP + Phaco: 20.6 ± 5.4 (range: 12 to 30)</p> <p>Trabectome + Phaco: 18.7 ± 4.7 (range: 11 to 30)</p> <p>P = 0.30</p>	<p>ECP + Phaco: 2.0 ± 1.0 (range: 0 to 4)</p> <p>Trabectome + Phaco: 1.3 ± 1.2 (range: 0 to 4)</p> <p>P = 0.06</p>	<p>VF (dB): ECP + Phaco: -9.1 ± 5.7</p> <p>Trabectome + Phaco: -8.0 ± 4.3</p> <p>P = NS</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	<p>Age: ECP + Phaco: 69.58 y ± 9.85 y (range: 48 y to 84 y)</p> <p>Trabectome + Phaco: 61.84 y ± 15.03 y (range: 30 y to 85 y)</p> <p><i>P</i> = 0.01</p> <p>Sex: n = 24 female; n = 37 male</p> <p>Race: Iranian</p>	<p>PXF, 10 (38.5%)</p> <p>Glaucoma severity, n (%): ECP + Phaco: Mild, 13 (37.1%); moderate, 9 (25.7%); severe, 13 (37.1%)</p> <p>Trabectome + Phaco: Mild, 9 (34.6%); moderate, 9 (34.6%); severe, 8 (30.8%)</p> <p><i>P</i> = NR</p>				
MIGS + Phaco Vs. Filtration Surgery + Phaco						
Ting et al. 2018 ⁸⁷	<p>Sample size: N = 19 eyes (19 patients)</p> <p>Trabectome + Phaco, n = 10 eyes (10 patients)</p> <p>Trabeculectomy + Phaco, n = 9 eyes (9 patients)</p> <p>Age: Trabectome + Phaco: 71.3 y ± 6.3 y</p> <p>Trabeculectomy + Phaco: 67.4 y ± 5.9 y</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma, n (%): Trabectome + Phaco: POAG, 7 (70%); PXF, 3 (30%)</p> <p>Trabeculectomy + Phaco: POAG, 6 (67%); PXF, 3 (33%)</p> <p><i>P</i> = 0.88</p> <p>Glaucoma severity, n (%): Trabectome + Phaco:</p>	<p>Previous ocular procedures: Trabectome + Phaco: SLT, 2 (20%); ALT, 1 (10%)</p> <p>Trabeculectomy + Phaco: SLT, 1 (11%); ALT, 0 (0%)</p> <p><i>P</i> = 0.31</p> <p>Comorbidities: Cataract; others NR</p>	<p>Trabectome + Phaco: 20.0 ± 5.3</p> <p>Trabeculectomy + Phaco: 23.1 ± 6.4</p> <p><i>P</i> = 0.22</p>	<p>Trabectome + Phaco: 1.80 ± 1.31</p> <p>Trabeculectomy + Phaco: 1.40 ± 1.13</p> <p><i>P</i> = 0.59</p>	NR

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	<p>$P = 0.23$</p> <p>Sex: n = 9 female; n = 10 male</p> <p>Race, n (%): Trabectome + Phaco: Caucasian, 9 (90%); African American, 1 (10%); Hispanic, 0 (0%)</p> <p>Trabeculectomy + Phaco: Caucasian, 8 (89%); African American, 0 (0%); Hispanic, 1 (11%)</p> <p>$P = 0.37$</p>	<p>Mild, 3 (30%); moderate, 6 (60%); advanced, 1 (10%)</p> <p>Trabeculectomy + Phaco: Mild, 4 (44%); moderate, 3 (33%); advanced, 2 (22%)</p> <p>$P = 0.49$</p>				
Kinoshita-Nakano et al. 2018 ⁸⁵	<p>Sample size: N = 76 eyes (76 patients)</p> <p>Trabectome + Phaco, n = 47 eyes (47 patients)</p> <p>Trabeculectomy + Phaco, n = 29 eyes (29 patients)</p> <p>Age: Trabectome + Phaco: 71.0 y ± 8.6 y (range: 52 y to 85 y)</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma, n: Trabectome: POAG, 27; exfoliation, 15; secondary, 5</p> <p>Trabeculectomy: POAG, 16; exfoliation, 10; secondary, 3 $P = 0.97$</p> <p>Glaucoma severity: NR</p>	<p>Previous ocular procedures: NR</p> <p>Comorbidities: NR</p>	<p>Trabectome + Phaco: 21.0 ± 5.7 (range: 13 to 37.5)</p> <p>Trabeculectomy + Phaco: 23.0 ± 7.0 (range: 15 to 40)</p> <p>$P = 0.33$</p>	<p>Trabectome + Phaco: 3.2 ± 0.9 (range: 1 to 5)</p> <p>Trabeculectomy + Phaco: 3.1 ± 0.8 (range: 2 to 5)</p> <p>$P = 0.49$</p>	<p>VF mean deviation (dB): Trabectome + Phaco: -11.60 ± 8.12</p> <p>Trabeculectomy + Phaco: -15.38 ± 8.39</p> <p>$P = 0.071$</p> <p>VA (logMAR): Trabectome + Phaco: 0.16 ± 0.29</p> <p>Trabeculectomy + Phaco: 0.31 ± 0.49</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
	<p>Trabeculotomy + Phaco: 72.5 y ± 6.2 y (range: 55 y to 81 y) <i>P</i> = 0.42</p> <p>Sex: n = 42 female; n = 34 male</p> <p>Race: Japanese</p>					<i>P</i> = 0.29
Marco et al. 2017 ⁸²	<p>Sample size: N = 53 eyes (53 patients)</p> <p>ECP + Phaco, n = 24</p> <p>Trab + Phaco (Trabeculectomy with MMC + Phaco), n = 29</p> <p>Age: ECP + Phaco: 68.8 y ± 11.3 y (range: 43 y to 84 y)</p> <p>Trab + Phaco: 73.1 y ± 13.2 y (range: 38 y to 92 y) <i>P</i> = 0.144</p> <p>Sex: n = 27 female; n = 26 male</p> <p>Race: NR</p>	<p>Type of eyes: NR</p> <p>Type of glaucoma, n (%): ECP + Phaco: POAG, 12 (50.0%); PXF, 2 (8.3%); Neovascular, 1 (4.2%); Uveitic, 1 (4.2%); PACG, 6 (25.0%); Plateau iris, 2 (8.3%)</p> <p>Trab + Phaco: POAG, 21 (72.4%); PXF, 4 (13.8%); Neovascular, 0 (0%); Uveitic, 1 (3.5%); PACG, 3 (10.3%); Plateau iris, 0 (0%)</p> <p><i>P</i> values for between-group comparisons all <i>P</i> > 0.05</p>	<p>Previous ocular procedures, n (%): ECP + Phaco: ALT/SLT, 3 (12.5%); LPI, 6 (25.0%); Trabeculectomy, 2 (8.3%); Tube, 1 (4.2%)</p> <p>Trab + Phaco: ALT/SLT, 3 (10.3%); LPI, 5 (17.2%); Trabeculectomy, 1 (3.5%); Tube, 0 (0%)</p> <p><i>P</i> values for between-group comparisons all <i>P</i> > 0.05</p> <p>Comorbidities: Past ocular history: ECP + Phaco: PDR, 2 (8.3%); AMD, 2 (8.3%);</p>	<p>ECP + Phaco: 19.9 ± 10.2</p> <p>Trab + Phaco: 19.2 ± 7.2</p> <p><i>P</i> = 0.589</p>	<p>ECP + Phaco: 2.5 ± 1.2</p> <p>Trab + Phaco: 2.7 ± 1.2</p> <p><i>P</i> = 0.667</p>	<p>VA (logMAR): ECP + Phaco: 0.656 ± 0.59</p> <p>Trab + Phaco: 0.620 ± 0.58</p> <p><i>P</i> = 0.670</p>

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
		<p>Glaucoma severity: NR</p> <p>Note: Those with healthy conjunctiva were assigned to the Trab + Phaco group; those with thinner conjunctiva underwent ECP + Phaco.</p>	<p>RVO, 1 (4.2%); Uveitis, 1 (4.2%); RD, 1 (4.2%)</p> <p>Trab + Phaco: PDR, 0 (0%); AMD, 1 (3.5%); RVO, 2 (6.9%); Uveitis, 2 (6.9%); RD, 0 (0%)</p> <p><i>P</i> values for between-group comparisons all <i>P</i> > 0.05</p> <p>Other comorbidities, n (%): ECP + Phaco: Asthma, 3 (12.5%); diabetes mellitus, 3 (12.5%); hypertension, 5 (20.8%); CVA, 1 (4.2%); thyroid, 0 (0%)</p> <p>Trab + Phaco: asthma, 0 (0%); diabetes mellitus, 2 (6.9%); hypertension, 8 (27.6%); CVA, 0 (0%); thyroid, 1 (3.5%)</p>			

Study Citation	Sample Size, Age, Sex, Race	Type of Eyes, ^b Type of Glaucoma, Glaucoma Severity	Previous Ocular Procedure(s), Relevant Comorbidities	Baseline IOP (mm Hg), Mean ± SD	Baseline Number of Glaucoma Medications, Mean ± SD	Baseline Visual Field, Visual Impairment, and/or Visual Acuity
			<i>P</i> values for between-group comparisons all <i>P</i> > 0.05			

1x = one device; 2x = two devices; 3x = three devices; AGI = Ahmed glaucoma implant; ALT = argon laser trabeculoplasty; AMD = age-related macular degeneration; BAT = brightness acuity test; BCVA = best-corrected visual acuity; BGI = Baerveldt glaucoma implant; CACG = chronic angle-closure glaucoma; CDVA = corrected-distance visual acuity; CVA = cerebral vascular accident; dB = decibel; DIOP = diurnal intraocular pressure; ECP = endoscopic cyclophotocoagulation; GDD = glaucoma drainage device; GDD-2 = second Baerveldt glaucoma implant 250 or 350; GI = glaucoma index; HFV = Humphrey visual field; Hydrus = Hydrus Microstent; ICD-9 = International Classification of Diseases 9; IOL = intraocular lens; IOP = intraocular pressure; IQR = inter-quartile range; KDB = Kahook Dual Blade; logMAR = logarithm of the minimum angle of resolution; LP = light perception; LPI = laser peripheral iridotomy; MDALL = Medical Devices Active Licence Listing; MICS = micro-incision cataract surgery; MIGS = minimally invasive glaucoma surgery; MMC = mitomycin C; NR = not reported; NS = non-significant; OAG = open-angle glaucoma; PACG = primary angle-closure glaucoma; PDR = proliferative diabetic retinopathy; Phaco = phacoemulsification; Phaco-ECP = phacoemulsification plus endoscopic cyclophotocoagulation; POAG = primary open-angle glaucoma; PSD = pattern standard deviation; PXF = pseudoexfoliative glaucoma; RD = retinal detachment; RVO = retinal vein occlusion; SD = standard deviation; SLT = selective laser trabeculoplasty; Trab + Phaco = Trabeculectomy with mitomycin C + Phacoemulsification; VA = visual acuity; VF = visual field; vs. = versus; y = year.

^a Unless otherwise stated, all values are means ± standard deviations.

^b Whether eyes contained the natural (phakic) lens or were pseudophakic, if reported.